Log In
BCIQ
Print this Print this
 

Kybella, deoxycholic acid (ATX-101)

  Manage Alerts
Collapse Summary General Information
Company Allergan plc
DescriptionSynthetic sodium deoxycholate
Molecular Target
Mechanism of Action 
Therapeutic ModalitySmall molecule
Latest Stage of DevelopmentMarketed
Standard IndicationBody Fat
Indication DetailsReduce submental (under chin) fat; Treat lipoma
Regulatory Designation U.S. - Standard Review (Reduce submental (under chin) fat)
Partner

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments

2

$2,100.0M

$1,723.0M

$330.0M


 Deals Details
DateCompanies InvolvedDeal HeadlineTotal Deal ValueTotal Upfront CashTotal Milestone

10/01/2015

$2,100.0M

$1,680.0M

0

09/06/2010

Undisclosed

$43.0M

$330.0M

Get a free BioCentury trial today